Researchers at the Icahn School of Medicine at Mount Sinai have identified a single amino acid difference between rodent- and human-derived Andes virus isolates that changes how a key viral protein behaves inside human cells. The study, published in Science Advances, found that the difference affects how an Andes virus glycoprotein moves through the cell and how quickly virus-like particles are released.
Andes virus is a rodent-borne RNA virus that can cause hantavirus pulmonary syndrome, a severe and potentially life-threatening illness. Unlike other known hantaviruses, it can spread from person to person. It was the virus involved in the fatal 2026 outbreak aboard the cruise ship Hondius.
The team, based in the lab of Gustavo Palacios, compared an Andes virus isolate from a rodent host with a human-derived isolate from the 2018-2019 outbreak in Epuyén, Argentina. That outbreak involved person-to-person transmission and resulted in 11 deaths. Earlier work had found biological differences between the two genetically similar isolates.
Search Antibodies Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.
The researchers identified 25 amino acid differences between the isolates and focused on one near the glycoprotein cleavage domain, because of its potential relevance to glycoprotein processing and virus assembly.
The rodent-derived isolate grew faster, although both isolates eventually reached similar levels. Viral RNA production showed no major changes that could explain the gap, so the team looked at later stages of the viral lifecycle. They changed one amino acid in the human-derived isolate’s glycoprotein to match the rodent-derived version. The modified protein spent less time in the Golgi apparatus, a cell compartment involved in protein processing, and virus-like particles were released more quickly.
“We still know relatively little about the viral features that may influence how Andes virus behaves in humans,” said Palacios. “What this study gives us is a specific molecular difference that we can connect to a measurable biological change.”
First author Santiago Vidal-Freire, said the finding could also point toward new antiviral targets. “Understanding how such a small molecular difference can affect viral protein processing and the release of new viral particles could help identify new targets for antiviral therapies.”
The authors stress the study’s limits. The work used molecular expression systems and virus-like particles, not genetically modified infectious Andes virus, so the results do not show that this amino acid change causes person-to-person transmission or adaptation to humans. Further research is needed to determine its effects in the complete virus and any link to disease or transmission.